Парсабив
Парсабив Uses, Dosage, Side Effects, Food Interaction and all others data.
Парсабив is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. Парсабив was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.
Following a single intravenous bolus administration of etelcalcetide, PTH levels decreased within 30 minutes post dose. In the single-dose study, the extent and duration of the reduction in PTH increased with increasing dose. Reduction in PTH levels correlated with plasma etelcalcetide concentrations in hemodialysis patients. The reduction in PTH resulted in reductions in calcium and attenuation of post-dialytic phosphate elevation. The effect of reducing PTH levels was maintained throughout the 6-month dosing period when etelcalcetide was administered by intravenous bolus three times a week.
Trade Name | Парсабив |
Availability | Prescription only |
Generic | Etelcalcetide |
Etelcalcetide Other Names | Etelcalcetida, Etelcalcetide, ételcalcétide, Etelcalcetidum, Velcalcetide |
Related Drugs | Rayaldee, Parsabiv, calcifediol |
Type | |
Formula | C38H73N21O10S2 |
Weight | Average: 1048.26 Monoisotopic: 1047.529069983 |
Protein binding | Etelcalcetide is predominately bound to plasma albumin by reversible covalent binding. Non-covalent binding of etelcalcetide to plasma proteins is low with a fraction unbound ratio of 0.53. The ratio of blood-to-plasma [14C]-etelcalcetide concentrations is approximately 0.6. |
Groups | Approved, Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | Russia |
Last Updated: | September 19, 2023 at 7:00 am |
![Парсабив Парсабив](https://www.medicinesfaq.com/media/png/parsabiv-.png)
Uses
Парсабив is a calcium sensing receptor agonist used to treat secondary hyperparathyroidism in patients with chronic kidney disease who require hemodialysis.
Парсабив is a calcium-sensing receptor agonist indicated for: Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
Парсабив is also used to associated treatment for these conditions: Secondary Hyperparathyroidism (SHPT)
How Парсабив works
Парсабив is a calcimimetic agent that allosterically modulates the calcium-sensing receptor (CaSR). Парсабив binds to the CaSR and enhances activation of the receptor by extracellular calcium. Activation of the CaSR on parathyroid chief cells decreases PTH secretion.
Food Interaction
No interactions found.Парсабив Disease Interaction
Volume of Distribution
796 L
Elimination Route
The pharmacokinetics of etelcalcetide is linear and does not change over time following single (5 to 60 mg) and multiple intravenous doses (2.5 to 20 mg) in chronic kidney disease patients with secondary hyperparathyroidism requiring hemodialysis. Парсабив exhibited tri-exponential decay following intravenous administration. Based on population pharmacokinetic analysis, following three times a week intravenous dosing at the end of each 3- to 6-hour hemodialysis session in chronic kidney disease patients, etelcalcetide plasma levels reached steady state in 7-8 weeks after dosing with a predicted accumulation ratio of 3- to 4-fold
Half Life
3 to 4 days
Clearance
7.66 L/hr
Elimination Route
Парсабив is cleared by renal excretion
Innovators Monograph
You find simplified version here Парсабив